Zobrazeno 1 - 5
of 5
pro vyhledávání: '"GOAL study"'
Autor:
Niki Karachaliou, MD, PhD, Oscar Arrieta, MD, Ana Giménez-Capitán, BSc, Erika Aldeguer, BSc, Ana Drozdowskyj, PhD, Imane Chaib, PhD, Noemí Reguart, MD, PhD, Rosario Garcia-Campelo, MD, Jing-Hua Chen, MD, Miguel Angel Molina-Vila, PhD, Rafael Rosell, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100113- (2021)
Introduction: DNA repair capacity, as exemplified by BRCA1 gene expression, is related with outcome to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant NSCLC. Olaparib, a PARP inhibitor, reduces BRCA1 expression. Olaparib was tested in co
Externí odkaz:
https://doaj.org/article/08a2152e29af4e089606394482732718
Autor:
Rosario García-Campelo, Noemí Reguart, Oscar Arrieta, Ana Giménez-Capitán, Niki Karachaliou, Ana Drozdowskyj, Rafael Rosell, Imane Chaib, Miguel Angel Molina-Vila, Erika Aldeguer, Jing-Hua Chen
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100113-(2021)
JTO Clinical and Research Reports
JTO Clinical and Research Reports
Introduction DNA repair capacity, as exemplified by BRCA1 gene expression, is related with outcome to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant NSCLC. Olaparib, a PARP inhibitor, reduces BRCA1 expression. Olaparib was tested in com
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Karachaliou N; Pangaea Oncology, Quirón-Dexeus University Hospital, Barcelona, Spain.; Instituto Oncológico Dr Rosell (IOR), University Hospital Sagrat Cor, Quirón Salud Group, Barcelona, Spain., Arrieta O; Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico., Giménez-Capitán A; Pangaea Oncology, Quirón-Dexeus University Hospital, Barcelona, Spain., Aldeguer E; Pangaea Oncology, Quirón-Dexeus University Hospital, Barcelona, Spain., Drozdowskyj A; Molecular and Cellular Oncology Laboratory, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Spain., Chaib I; Molecular and Cellular Oncology Laboratory, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Spain., Reguart N; Medical Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain., Garcia-Campelo R; Medical Oncology Department, University Hospital A Coruña (XXIAC-SERGAS), A Coruña, Spain., Chen JH; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.; Medical Oncology Department, Guangzhou Twelfth People's Hospital, Guangzhou, People's Republic of China., Molina-Vila MA; Pangaea Oncology, Quirón-Dexeus University Hospital, Barcelona, Spain., Rosell R; Pangaea Oncology, Quirón-Dexeus University Hospital, Barcelona, Spain.; Molecular and Cellular Oncology Laboratory, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Spain.
Publikováno v:
JTO clinical and research reports [JTO Clin Res Rep] 2020 Oct 23; Vol. 2 (3), pp. 100113. Date of Electronic Publication: 2020 Oct 23 (Print Publication: 2021).